Immunological response in subjects who received Pfizer
| Withhold therapy | Continue therapy | Controls | Total | |
| Detectable SARS-CoV2 antibodies* | ||||
| Post first vaccine dose | 37/44 (84.1) | 31/48 (64.58) | 27/27 (100) | 95/119 (79.83) |
| Withhold versus continue (p=0.056) | ||||
| Withhold versus controls (p=0.039) | ||||
| Continue versus controls (p=0.000) | ||||
| Post second vaccine dose | 42/42 (100) | 47/49 (95.9) | 27/27 (100) | 116/118 (98.31) |
| Withhold versus continue (p=0.497) | ||||
| Withhold versus controls | ||||
| Continue versus controls (p=0.413) | ||||
| Mean SARS-CoV2 Ab titre† | ||||
| Post first vaccine dose | 7.36 (9.79) | 4.94 (7.19) | 11.05 (11.82) | 7.24 (9.59) |
| Withhold versus continue (p=0.019) | 3.4 (8.7) | 1.85 (7.1) | 5.1 (10.2) | 3.4 (8.8) |
| Withhold versus controls (p=0.052) | ||||
| Continue versus controls (p=0.000) | ||||
| Post second vaccine dose | 136.02 (169.68) | 76.18 (77.63) | 133.58 (166.26) | 110.40 (139.53) |
| Withhold versus continue (p=0.032) | 73.7 (111.3) | 50.8 (92) | 66.8 (78.3) | 66.8 (97.2) |
| Withhold versus controls (p=0.980) | ||||
| Continue versus controls (p=0.033) |
Data are presented as proportions (%) or mean (SD) and median (IQR).
*Using Fisher’s exact test with significance cut-off 5%.
†Using Wilcoxon-Mann-Whitney U test with significance cut-off 5%.
Ab, antibody.